

Approved



Papua New Guinea
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		2,032,798	2,500,000	4,532,798	0	4,532,798
HHS/CDC	300,000	1,272,202		1,572,202	300,000	1,872,202
HHS/HRSA		100,000		100,000	50,000	150,000
State/EAP		45,000		45,000	0	45,000
Total	300,000	3,450,000	2,500,000	6,250,000	350,000	6,600,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency				On Hold Amount	Total
	State/EAP	HHS/CDC	HHS/HRSA	USAID		
HBHC		30,000		99,865	0	129,865
HLAB		143,260		319,404	0	462,664
HTXD		57,440			0	57,440
HTXS		419,873	75,000	708,046	0	1,202,919
HVCT				375,179	0	375,179
HVMS		438,989		572,426	0	1,011,415
HVOP	45,000			1,795,709	0	1,840,709
HVSI		235,940		477,674	0	713,614
HVTB		119,933	25,000	184,495	0	329,428
OHSS		126,767		0	0	126,767
	45,000	1,572,202	100,000	4,532,798	0	6,250,000



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	126,631	0
HVTB	273,027	0
Total Technical Area Planned Funding:	399,658	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	380,000	0
HVSI	547,330	0
OHSS	30,000	0
Total Technical Area Planned Funding:	957,330	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	362,242	0
HVOP	1,766,137	0
Total Technical Area Planned Funding:	2,128,379	0

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXS	1,043,613	0
Total Technical Area Planned Funding:	1,043,613	0

Approved





Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,500
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
Denominator: Age/sex: 50+ Male		
Denominator: Age/sex: 10-14		



	Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	708
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	792
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,500
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of	640



	key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	416
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	1,444



	required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type:	



	Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	



	By New Client Status: RReturning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,700
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female		
Test Result by Age and Sex: Positive: 15-19 Female		



	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,543
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
	Aggregated Age/sex - USE WITH	2,157



	HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	0
	Test Result by Aggregated Age and Sex: Positive 15+ Male	85
	Test Result by Aggregated Age and Sex: Positive <15 Female	0
	Test Result by Aggregated Age and Sex: Positive 15+ Female	123
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	



	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	3,700
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	



	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	



	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,857
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
Test Result by Age and Sex: Positive: 10-14 Female		
Test Result by Age and Sex:		



	Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	750
	Aggregated Age/sex - USE WITH	16



	HQ PERMISSION ONLY: <15 Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,072
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	5
	Test Result by Aggregated Age and Sex: Positive 15+ Male	44
	Test Result by Aggregated Age and Sex: Positive <15 Female	1
	Test Result by Aggregated Age and Sex: Positive 15+ Female	74
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community)	



	by Age: <15 index testing	
	Service Delivery Point (Community)	
	by Age: 15+ index testing	
	Service Delivery Point (Community)	
	by Age: <15 homebased testing	
	Service Delivery Point (Community)	
	by Age: 15+ homebased testing	
	Service Delivery Point (Community)	
	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	1,857
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	
	Service Delivery Point (Facility): TB Clinics	
	Service Delivery Point (Facility):	



	Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
GEND_GBV_DSD	Number of people receiving post-GBV care	150
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	100
	By type of service: Sexual Violence (Post-Rape Care)	50
	By PEP service provision (related to sexual violence services provided)	20
	Age/Sex: 15-19 Female	



	Age/Sex: 15-19 male	
GEND_GB_V_TA	Number of people receiving post-GBV care	50
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	50
	By PEP service provision (related to sexual violence services provided)	25
Age/Sex: 15-19 Female		
Age/Sex: 15-19 Male		
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	368
	Screened for TB by Age/Sex:<15 Male	
	Screened for TB by Age/Sex: 15+ Male	150
	Screened for TB by Age/Sex:<15	



	Female	
	Screened for TB by Age/Sex: 15+ Female	218
	Screen Result: Screened Positive for TB	
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	386
	Screened for TB by Age/Sex: <15 Male	5
	Screened for TB by Age/Sex: 15+ Male	128
	Screened for TB by Age/Sex: <15 Female	25
	Screened for TB by Age/Sex: 15+ Female	228
	Screen Results: Screened Positive	



	for TB	
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	410
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	
	Aggregated Age/Sex: 15+ Male	166
	Aggregated Age/Sex: <15 Female	
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	244
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	410
	Sum of Aggregated Age/Sex	410



	disaggregates	
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)
Age/Sex: <1 Male		
Age/Sex: 1-4 Male		
Age/Sex: 5-14 Male		
Age/Sex: 15-19 Male		
Age/Sex: 20+ Male		
Age/Sex: <1 Female		
Age/Sex: 1-4 Female		
Age/Sex: 5-14 Female		
Age/Sex: 15-19 Female		
Age/Sex: 20+ Female		
Sum of Age/Sex disaggregations		
Aggregated Age/Sex: <1 Male		
Aggregated Age/Sex: <1 Female		
Aggregated Age/Sex: <15 Male		27
Aggregated Age/Sex: 1-14 Male		



	Aggregated Age/Sex: 15+ Male	159
	Aggregated Age/Sex: <15 Female	6
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	276
	Sum of Aggregated Age/Sex <15	33
	Sum of Aggregated Age/Sex 15+	435
	Sum of Aggregated Age/Sex disaggregates	468
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	187
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	



	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	76
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	111
	Sum of Aggregated Age/Sex disaggregates	187
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	113
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	



	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	4
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	40
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	68
	Sum of Aggregated Age/Sex disaggregates	113



	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	45
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	50
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	45
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication:	



	10-14 Male Routine	
	Numerator: Age/Sex by Indication:	
	15-19 Male Routine	
	Numerator: Age/Sex by Indication:	
	20-24 Male Routine	
	Numerator: Age/Sex by Indication:	
	25-49 Male Routine	
	Numerator: Age/Sex by Indication:	
	50+ Male Routine	
	Numerator: Age/Sex by Indication:	
	10-14 Female Routine	
	Numerator: Age/Sex by Indication:	
	15-19 Female Routine	
	Numerator: Age/Sex by Indication:	
	20-24 Female Routine	
	Numerator: Age/Sex by Indication:	
	25-49 Female Routine	
	Numerator: Age/Sex by Indication:	
	50+ Female Routine	
	Numerator: Age/Sex by Indication:	
	<1 Targeted	
	Numerator: Age/Sex by Indication:	
	1-9 Targeted	
	Numerator: Age/Sex by Indication:	
	10-14 Male Targeted	
	Numerator: Age/Sex by Indication:	
	15-19 Male Targeted	
	Numerator: Age/Sex by Indication:	
	20-24 Male Targeted	
	Numerator: Age/Sex by Indication:	
	25-49 Male Targeted	
	Numerator: Age/Sex by Indication:	
	50+ Male Targeted	
	Numerator: Age/Sex by Indication:	



	10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	50
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by	



	Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex:	18



	15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	27
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	20
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	30
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	163
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	



	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	



	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	
	Numerator: Indication: Targeted	13
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	



	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	
	Denominator: Indication: Targeted	14
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	



	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	



	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	5
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	8
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	5
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	9
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	144
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	160



	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on	



	treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those	



	who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	



	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	64



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	90
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	100
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator:	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
	Aggregated Age/Sex: 15+ Male	30



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	2

Approved



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
17083	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,708,980
17091	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
17597	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of East Asian and Pacific Affairs	GHP-State	45,000
17917	TBD	TBD	Redacted	Redacted	Redacted
17920	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	100,000
18249	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	200,000

Approved



			Prevention		
18255	UNAIDS II	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 17083	Mechanism Name: Strengthening HIV/AIDS Services for MARPs in PNG Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,708,980	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,708,980	
Funding Source	Funding Amount
GHP-State	1,208,980
GHP-USAID	2,500,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	543,185
Key Populations: MSM and TG	1,641,881
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	883,555



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	787,297
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	28,949

Budget Code Information

Mechanism ID:	17083
Mechanism Name:	Strengthening HIV/AIDS Services for MARPs in PNG Program
Prime Partner Name:	FHI 360



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	96,631	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	178,027	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	394,830	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	362,242	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,721,137	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	656,113	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,500



PP_PREV_DSD	Aggregated Age/sex: 15+ Male	708
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	792
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,500
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	640
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	416
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,444
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,700
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,543
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,157
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,700
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,700



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	85
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	123
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	3,700
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,857
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	19
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	750
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,072
HTC_TST_TA	Sum of Aggregated Age/Sex <15	35
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,822
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	1,857
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	5
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	44
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	74
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,857
GEND_GBV_DSD	Number of people receiving post-GBV care	150
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	100



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	50
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	20
GEND_GBVTAT	Number of people receiving post-GBV care	50
GEND_GBVTAT	By type of service: Sexual Violence (Post-Rape Care)	50
GEND_GBVTAT	By PEP service provision (related to sexual violence services provided)	25
TB_SCREENDXDSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	368
TB_SCREENDXDSD	Screened for TB by Age/Sex: 15+ Male	150
TB_SCREENDXDSD	Screened for TB by Age/Sex: 15+ Female	218
TB_SCREENDXTAT	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	386
TB_SCREENDXTAT	Screened for TB by Age/Sex: <15 Male	5
TB_SCREENDXTAT	Screened for TB by Age/Sex: 15+ Male	128
TB_SCREENDXTAT	Screened for TB by Age/Sex: <15 Female	25
TB_SCREENDXTAT	Screened for TB by Age/Sex: 15+ Female	228
TX_CURRDSD	Number of adults and children receiving antiretroviral therapy (ART)	410
TX_CURRDSD	Aggregated Age/Sex: 15+ Male	166
TX_CURRDSD	Aggregated Age/Sex: 15+ Female	244
TX_CURRDSD	Sum of Aggregated Age/Sex 15+	410
TX_CURRDSD	Sum of Aggregated Age/Sex disaggregates	410
TX_CURRTAT	Number of adults and children receiving antiretroviral therapy (ART)	468
TX_CURRTAT	Aggregated Age/Sex: <15 Male	27
TX_CURRTAT	Aggregated Age/Sex: 15+ Male	159
TX_CURRTAT	Aggregated Age/Sex: <15 Female	6
TX_CURRTAT	Aggregated Age/Sex: 15+ Female	276
TX_CURRTAT	Sum of Aggregated Age/Sex <15	33



TX_CURR_TA	Sum of Aggregated Age/Sex 15+	435
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	468
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	187
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	76
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	111
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	187
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	113
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	4
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	40
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	68
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	113
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	45
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	50
TX_PVLS_DSD	Numerator: Indication: Targeted	45
TX_PVLS_DSD	Denominator: Indication: Targeted	50
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	18
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	27
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	20
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	30
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	14



	and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Numerator: Indication: Targeted	13
TX_PVLS_TA	Denominator: Indication: Targeted	14
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	5
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	8
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	5
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	9
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	144
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	160
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	90
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	100



	stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59

Implementing Mechanism Details

Mechanism ID: 17091	Mechanism Name: World Health Organization
----------------------------	--



	PNG
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 375,000	
Applied Pipeline Amount: 125,000	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	375,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	140,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	220,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients



Budget Code Information

Mechanism ID: 17091			
Mechanism Name: World Health Organization PNG			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	102,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	182,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	150

Implementing Mechanism Details

Mechanism ID: 17597	Mechanism Name: Ambassador's Small Grants Program PNG
----------------------------	--

Approved



Funding Agency: State/EAP	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 45,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 45,000	
Funding Source	Funding Amount
GHP-State	45,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17597			
Mechanism Name: Ambassador's Small Grants Program PNG			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	45,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17917	TBD: Yes
----------------------------	-----------------



REDACTED

Implementing Mechanism Details

Mechanism ID: 17920	Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 50,000	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17920			
Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)			
Prime Partner Name: Health Research Inc./New York State Department of Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	25,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	75,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18249	Mechanism Name: Foundation for Innovative New Diagnostics
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:
Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	50,000



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients

Budget Code Information

Mechanism ID:	18249		
Mechanism Name:	Foundation for Innovative New Diagnostics		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	80,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 18255	Mechanism Name: UNAIDS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS II	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	2,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	2,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Key Populations: MSM and TG	2,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs



Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	2,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID: 18255			
Mechanism Name: UNAIDS			
Prime Partner Name: UNAIDS II			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		10,000		0	10,000	10,000
ICASS		135,206		0	135,206	135,206
Management Meetings/Professional Development		55,499		0	55,499	55,499
Non-ICASS Administrative Costs		5,000		0	5,000	5,000
Staff Program Travel		92,476		0	92,476	92,476
USG Staff Salaries and Benefits - Internationally Recruited		366,677		0	366,677	366,677
USG Staff Salaries and Benefits - Locally Recruited		158,960		0	158,960	158,960
Total	0	823,818	0	0	823,818	823,818



U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		101,445		0	101,445	101,445
Computers/IT Services		15,000		0	15,000	15,000
Indirect Costs		242,509		0	242,509	242,509
Institutional Contractors				0	0	0
Management Meetings/Professional Development		25,000		0	25,000	25,000
Non-ICASS Administrative Costs		24,248		0	24,248	24,248
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		62,000		0	62,000	62,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff	300,000	127,000		175,000	427,000	602,000

Approved



Salaries and Benefits - Locally Recruited						
Total	300,000	597,202	0	175,000	897,202	1,072,202